Summary
- Inhibikase Therapeutics has filed for an $18 million U.S. IPO.
- The firm is developing treatments for Parkinson's Disease and other neurodegenerative disorders.
- IKT is thinly capitalized and still at pre-Phase 1 stage, so the IPO is ultra high risk.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Inhibikase Therapeutics (IKT) has filed to raise $18 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is advancing a pipeline of treatments for Parkinson's Disease and other neurodegenerative disorders.
IKT is pursuing treatment areas that have proven to be very difficult for major pharma firms to make progress in.
I’ll provide a final opinion when we learn more about the IPO.
Company & Technology
Atlanta, Georgia-based Inhibikase was founded to develop small molecule inhibitory drugs to treat Parkinson's Disease, cancer and other conditions.
Management is headed by founder, president and Chief Executive Officer Mr. Milton Werner, Ph.D., who was previously Director of Research at Celtaxsys, a cell-free immunotherapeutics company.
Below is a brief overview video of Parkinson's Disease:
